TIDMABDX
Abingdon Health PLC
02 March 2022
Abingdon Health plc
("Abingdon" or "the Company")
Data from UK Government led study gives insight into protection
from SARS-CoV-2
-- UK Government commissioned study working toward setting
antibody level thresholds to determine protection levels
-- Building case for antibody testing to support vaccine and workplace COVID-19 strategies
-- AbC-19(TM) Semi-Q Rapid Test (Semi-quantitative anti-spike
antibody test) results correlate with ONS findings
York, U.K. 2 March 2022 : Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, notes the publication of data(1) by the
Office for National Statistics (ONS) in making significant steps
forward in stratifying antibody thresholds for a better
understanding of protection against SARS-CoV-2 (COVID-19)
infection, supporting the case for mass antibody testing to guide
vaccine booster programmes and workplace COVID-19 policies.
The 'Coronavirus (COVID-19) Infection Survey, antibody and
vaccination data' recently published an antibody threshold
associated with a 67% lower risk of getting a new COVID-19
infection. This threshold was based on a study completed by The
University of Oxford, The University of Manchester, UK Health
Security Agency and Wellcome Trust, commissioned by the Department
for Health and Social Care (DHSC) (2) .
The study, which focused on the detection of antibodies against
the spike protein, identified a threshold of 179 ng/ml which
corresponds to 100 BAU/ml using the World Health Organization's
(WHO) standardised units(3) .
The study noted that the threshold was identified as providing a
67% lower risk of getting a new COVID-19 infection with the Delta
variant after two vaccinations with either Pfizer or AstraZeneca
vaccines, compared with someone who was unvaccinated and had not
had COVID-19 before.
This study also noted that "at least 67% protection against
infection was estimated to last for 2-3 months after two ChAdOx1
(Oxford AstraZeneca) doses and 5-8 months after two BNT162b2
(Pfizer) doses in those without prior infection, and 1-2 years for
those unvaccinated after natural infection". More data is to be
published in due course.
Such data supports the use of antibody testing in reducing the
guesswork around how individuals are responding to both vaccination
and/or infection. Each individual is different and antibody testing
is an important tool in helping populations to live with COVID-19.
For vaccine programmes it enables prioritisation of who and when
people require their next jab can be facilitated with antibody
testing. For unvaccinated but previously infected individuals it
provides some assurances of seroconversion and length of
protection.
Abingdon Health commercially launched a semi-quantitative IgG
rapid antibody test against the spike protein; AbC-19(TM) Semi-Q
Rapid Test ("AbC-19(TM) Semi-Q"). Using a scorecard, the antibody
concentration can be easily determined by aligning the obtained
score with a predetermined antibody concentration, allowing
individuals to reliably monitor immune response and antibody
waning.
Using the same WHO standard, preliminary results(4) indicate
that 100 BAU/ml equals a level 5 on the AbC-19(TM) Semi-Q Rapid
Test scorecard.
Furthermore, this threshold correlates with results produced in
a longitudinal antibody test user study. Data (See graph:
https://www.abingdonhealth.com/app/uploads/2022/02/AbC-19TM-Rapid-Test-Semi-Quantification-Post-Vaccination-Infection.pdf)
demonstrated that the father of one household who produced a level
four on the AbC-19(TM) Semi-Q scorecard, avoided catching COVID-19
from his son who tested positive. Whereas the mother of that
household, at a level one at the time, did subsequently catch the
virus and test positive for COVID-19.
Chris Yates, Chief Executive Officer of Abingdon Health,
commented: "We welcome the publication of this data in being very
significant for helping people to gain insights into protection
against COVID-19. We look forward to further results from this
study.
"The effects of COVID-19 continue. Accurately monitoring
antibody levels is important for determining if, and when, booster
vaccines are required. Our own research, as well as other published
data, shows there is a significant degree of variability in
antibody levels between individuals, following infection and/or
vaccination.
"It is our long-held belief that antibody testing is being under
used particularly as people want to know their antibody status.
This desire was certainly confirmed in results from an antibody
testing survey we published recently. We're passionate about making
meaningful rapid testing available to all to help empower people to
make informed decisions about their health. Antibody testing is
another means of empowerment."
References:
1. Coronavirus (COVID-19) Infection Survey, antibody and vaccination data, UK: 9 February 2022 (https:www.ons.gov.ukpeoplepopulationandcommunityhealthandsocialcareconditionsanddiseasesbulletinscoronaviruscovid19infectionsurveyantibodyandvaccinationdatafortheuklatest#analysis-using-an-alternative-antibody-threshold)
2. Wei, J et al (2022) SARS-CoV-2 anti-spike IgG antibody
responses after second dose of ChAdOx1 or BNT162b2 and correlates
of protection in the UK general population (pre-print)
https://doi.org/10.1101/2021.09.13.21263487
3. WHO International Standard First WHO International Standard
for anti-SARS-CoV-2 immunoglobulin (human) NIBSC code: 20/136
Instructions for use.
(https://www.nibsc.org/documents/ifu/20-136.pdf)
4. Journal of infection 83 (2021) e18-e3
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Christopher Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Shaun Dobson, Peter Steel, Alex Bond
(Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)7867 984
Marriage 082
Alice Woodings Mob: +44 (0)7407 804 654
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers lateral flow product development, regulatory
support, technology transfer and manufacturing services for
customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADBGDXIUGDGDB
(END) Dow Jones Newswires
March 02, 2022 02:01 ET (07:01 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Feb 2025 to Mar 2025
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Mar 2025
